AstraZeneca Joins the In-Licensing Game
Much of AstraZeneca's newly-in-licensed bounty is high-risk. But it provides a low-cost pipeline boost, and marks a sharp turnaround at the firm.
Much of AstraZeneca's newly-in-licensed bounty is high-risk. But it provides a low-cost pipeline boost, and marks a sharp turnaround at the firm.